Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer

被引：13
作者：
Tong, Ling [1 ,2 ]
Yu, Xiangling [1 ]
Wang, Shan [1 ,2 ]
Chen, Ling [2 ]
Wu, Yibo [1 ]
机构：
[1] Jiangnan Univ, Human Reprod & Genet Ctr, Affiliated Hosp, Wuxi 214062, Peoples R China
[2] Jiangnan Univ, Dept Breast Surg, Affiliated Hosp, Wuxi 214062, Peoples R China
来源：
BREAST CANCER-TARGETS AND THERAPY | 2023年 / 15卷
关键词：
triple-negative breast cancer; immunotherapy; targeted therapy; precision therapy; PEMBROLIZUMAB PLUS CHEMOTHERAPY; DOUBLE-BLIND; OPEN-LABEL; GLEMBATUMUMAB VEDOTIN; SACITUZUMAB GOVITECAN; PACLITAXEL; MULTICENTER; OLAPARIB;
D O I：
10.2147/BCTT.S426121
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Breast cancer has become the most common malignant tumor worldwide. Triple-negative breast cancer (TNBC) is a type of breast cancer that is negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Compared with other molecular subtypes of breast cancer, TNBC is the most aggressive and highly heterogeneous. TNBC is insensitive to endocrine and anti-HER2 therapy, and chemotherapy is currently the main systemic treatment. With the continuous development of detection techniques and deepening research on TNBC molecular subtypes, drugs targeting immune checkpoints and different targets have emerged, such as atezolizumab, pembrolizumab, poly (ADP-ribose) polymerase (PARP) inhibitors, trophoblast cell-surface antigen 2 (TROP-2), and antibody-drug conjugates. These therapies provide new hope for TNBC treatment. Based on the analysis and classification of TNBC, this article summarizes the immunotherapy, targeted therapy, and new treatment combinations, providing references for the precise treatment of TNBC in the future.
引用
收藏
页码：647 / 658
页数：12
相关论文
共 60 条
[1]  
Adams S, 2019, ANN ONCOL, V30, P405, DOI [10.1093/annonc/mdy518, 10.1093/annonc/mdy517]
[2]   Efficacy and safety of pembrolizumab based therapies in triple-negative breast cancer: A systematic review of clinical trials [J].
Ali, Muhammad Ashar ;
Aiman, Wajeeha ;
Shah, Syed S. ;
Hussain, Mahreen ;
Kashyap, Richi .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 157
[3]   Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications [J].
Asleh, Karama ;
Riaz, Nazia ;
Nielsen, Torsten O. .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
[4]   Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer [J].
Bardia, A. ;
Tolaney, S. M. ;
Punie, K. ;
Loirat, D. ;
Oliveira, M. ;
Kalinsky, K. ;
Zelnak, A. ;
Aftimos, P. ;
Dalenc, F. ;
Sardesai, S. ;
Hamilton, E. ;
Sharma, P. ;
Recalde, S. ;
Gil, E. C. ;
Traina, T. ;
O'Shaughnessy, J. ;
Cortes, J. ;
Tsai, M. ;
Vahdat, L. ;
Dieras, V ;
Carey, L. A. ;
Rugo, H. S. ;
Goldenberg, D. M. ;
Hong, Q. ;
Olivo, M. ;
Itri, L. M. ;
Hurvitz, S. A. .
ANNALS OF ONCOLOGY, 2021, 32 (09) :1148-1156
[5]   Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer [J].
Bardia, A. ;
Hurvitz, S. A. ;
Tolaney, S. M. ;
Loirat, D. ;
Punie, K. ;
Oliveira, M. ;
Brufsky, A. ;
Sardesai, S. D. ;
Kalinsky, K. ;
Zelnak, A. B. ;
Weaver, R. ;
Traina, T. ;
Dalenc, F. ;
Aftimos, P. ;
Lynce, F. ;
Diab, S. ;
Cortes, J. ;
O'Shaughnessy, J. ;
Dieras, V ;
Ferrario, C. ;
Schmid, P. ;
Carey, L. A. ;
Gianni, L. ;
Piccart, M. J. ;
Loibl, S. ;
Goldenberg, D. M. ;
Hong, Q. ;
Olivo, M. S. ;
Itri, L. M. ;
Rugo, H. S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16) :1529-1541
[6]   Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial [J].
Bernsdorf, Mogens ;
Ingvar, Christian ;
Jorgensen, Leif ;
Tuxen, Malgorzata K. ;
Jakobsen, Erik H. ;
Saetersdal, Anna ;
Kimper-Karl, Marie Louise ;
Kroman, Niels ;
Balslev, Eva ;
Ejlertsen, Bent .
BREAST CANCER RESEARCH AND TREATMENT, 2011, 126 (02) :463-470
[7]   Treatment landscape of triple-negative breast cancer - expanded options, evolving needs [J].
Bianchini, Giampaolo ;
De Angelis, Carmine ;
Licata, Luca ;
Gianni, Luca .
NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (02) :91-113
[8]   Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer [J].
Bracci, L. ;
Schiavoni, G. ;
Sistigu, A. ;
Belardelli, F. .
CELL DEATH AND DIFFERENTIATION, 2014, 21 (01) :15-25
[9]   Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer [J].
Chen, Xingyu ;
Feng, Lixiang ;
Huang, Yujing ;
Wu, Yi ;
Xie, Na .
CANCERS, 2023, 15 (01)
[10]   Evaluation of Racial/Ethnic Differences in Treatment and Mortality Among Women With Triple-Negative Breast Cancer [J].
Cho, Beomyoung ;
Han, Yunan ;
Lian, Min ;
Colditz, Graham A. ;
Weber, Jason D. ;
Ma, Cynthia ;
Liu, Ying .
JAMA ONCOLOGY, 2021, 7 (07) :1016-1023
123456